Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 3Phase 3 2Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Melanoma 106Carcinoma, Non-Small-Cell Lung 34Carcinoma, Renal Cell 23Prostatic Neoplasms 17Neoplasms 15Brain Neoplasms 15Neoplasm Metastasis 14Lung Neoplasms 12Breast Neoplasms 11Uveal Melanoma 10Pancreatic Neoplasms 10Sarcoma 9Small Cell Lung Carcinoma 7Urinary Bladder Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Kidney Neoplasms 6Diabetes Mellitus, Insulin-Dependent, 12 6Carcinoma, Transitional Cell 6Carcinoma, Hepatocellular 6Skin Neoplasms 5Ovarian Neoplasms 5Histiocytoma, Malignant Fibrous 5Colorectal Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Recurrence 4Neuroendocrine Tumors 4Mesothelioma 4Glioblastoma 4Colonic Neoplasms 4

Interventions

Cisplatin 131Cetuximab 80Radiotherapy 76Docetaxel 59Carboplatin 46pembrolizumab 45Paclitaxel 44Fluorouracil 42Radiotherapy, Intensity-Modulated 35Drug Therapy 17Radiation 14Nivolumab 14Gefitinib 14Gemcitabine 13Surgical Procedures, Operative 12Oxaliplatin 11Erlotinib Hydrochloride 11130-nm albumin-bound paclitaxel 11Pemetrexed 10Celecoxib 10Capecitabine 10Bevacizumab 10tislelizumab 9Filgrastim 9Amifostine 9Albumin-Bound Paclitaxel 9durvalumab 7atezolizumab 7Chemoradiotherapy 7toripalimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Head and Neck Neoplasms × Ipilimumab × Clear all
NCT02919683 2026-01-28

Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
30 enrolled 14 charts
Head & Neck

Head and Neck Neoplasms

NCT02823574 2023-05-03

CheckMate 714

Bristol-Myers Squibb

Phase 2 Completed
425 enrolled 46 charts
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡